Project Grant F31CA294887
Award Date
12/24/24
Completion Date
7/31/26
Dollars Obligated
$135K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Northwestern University provides $577,634 to investigate the role of the SEC61 protein complex in overcoming resistance to immunotherapy in glioblastoma (GBM), an aggressive form of brain cancer. The key objectives are to: 1) understand how SEC61G expression interacts with the MAPK pathway to contribute to T cell-mediated therapeutic resistance in glioma cells; 2) determine the impact of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $151,856 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the relationship between the hyper-thrombotic state and immunosuppression in glioblastoma (GBM), the most common primary malignant brain tumor. The research aims to: 1) investigate how GBM induces platelet hyperactivity and its impact on tumor growth, and 2)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas M.D. Anderson Cancer Center provides $432,134.00 in funding to establish a radiotheranostic approach for treating glioblastoma (GBM), a highly aggressive brain cancer, by targeting the IL13RA2 protein expressed on cancer cells. The research aims to develop human monoclonal antibodies that bind to IL13RA2 with high affinity and specificity, and evaluate the...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
The National Cancer Institute (NCI) awarded a $552,968 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh to conduct research on the role of tRNA modifications in glioblastoma stem cell maintenance and translational reprogramming. The project aims to use mass spectrometry and ribosome profiling to investigate how altered tRNA modifications influence the translational landscape and drive oncogenic processes in glioblastoma, a highly lethal...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 - Cancer Biology Research provides $552,874 in funding to The Regents of the University of California, San Francisco (UCSF) from August 1, 2024 to July 31, 2029. The project aims to dissect the cellular and molecular pathways by which the A20 protein regulates anti-tumor immunity. Specifically, the research will focus on understanding how A20, a potent regulator of immune homeostasis, restrains both acute and anamnestic...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...